Renal Cell Carcinoma in End-Stage Renal Disease: A Retrospective Study in Patients from Hungary.
Acquired cystic kidney disease
End-stage renal disease
Renal cell carcinoma
Journal
Pathobiology : journal of immunopathology, molecular and cellular biology
ISSN: 1423-0291
Titre abrégé: Pathobiology
Pays: Switzerland
ID NLM: 9007504
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
09
2022
accepted:
14
01
2023
medline:
1
11
2023
pubmed:
26
1
2023
entrez:
25
1
2023
Statut:
ppublish
Résumé
End-stage renal disease (ESRD) and acquired cystic kidney disease (ACKD) are known risk factors for renal cell carcinoma (RCC). Hereby, the clinicopathological features of RCCs developed in ESRD were investigated. A database consisting of 34 tumors from 31 patients with ESRD among 2,566 nephrectomy samples of RCC was built. The demographic, clinical, and follow-up data along with pathological parameters were analyzed. The RCCs were diagnosed according to the current WHO Classification of Urinary and Male Genital Tumors. Twenty-two tumors developed in men and 12 in women, with a median age of 56 years (range: 27-75 years). The causes of ESRD were glomerulonephritis (n = 7), hypertensive kidney disease (n = 6), autosomal dominant polycystic kidney disease (n = 6), chronic pyelonephritis (n = 4), diabetic nephropathy (n = 3), chemotherapy-induced nephropathy (n = 1), and undetermined (n = 4). ACKD complicated ESRD in 12 patients. The following histological subtypes were identified: clear cell RCC (n = 19), papillary RCC (n = 5), clear cell papillary tumor (n = 5), ACKD RCC (n = 3), and eosinophilic solid and cystic RCC (n = 2). The median tumor size was 31 mm (range: 10-80 mm), and 32 tumors were confined to the kidney (pT1-pT2). There was no tumor-specific death during the period of this study. Progression was registered in 1 patient. In our cohort, the most common RCC subtype was clear cell RCC (55%), with a frequency that exceeded international data appreciably (14-25%). The incidence of clear cell papillary tumor and ACKD RCC (14.7% and 8.5%) was lower than data reported in the literature (30% and 40%). Our results indicate a favorable prognosis of RCC in ESRD.
Identifiants
pubmed: 36696889
pii: 000529276
doi: 10.1159/000529276
pmc: PMC10614572
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
322-332Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Eur Urol. 2011 Aug;60(2):366-73
pubmed: 21377780
Pathol Int. 2018 Oct;68(10):543-549
pubmed: 30187581
Am J Surg Pathol. 2013 Oct;37(10):1469-89
pubmed: 24025519
Pathol Oncol Res. 2017 Jul;23(3):689-698
pubmed: 28032311
Pathol Oncol Res. 2020 Jul;26(3):1767-1776
pubmed: 31656019
Am J Surg Pathol. 2005 Apr;29(4):443-51
pubmed: 15767796
Virchows Arch. 2018 Dec;473(6):725-738
pubmed: 30232607
Mod Pathol. 2006 Jun;19(6):780-7
pubmed: 16575398
Int J Urol. 2018 Sep;25(9):780-786
pubmed: 30066367
Cancer Med. 2016 Aug;5(8):2101-8
pubmed: 27228559
Med Mol Morphol. 2010 Dec;43(4):231-4
pubmed: 21267700
Nephrol Dial Transplant. 1995;10(5):593-6
pubmed: 7566566
Am J Surg Pathol. 2018 Oct;42(10):1396-1401
pubmed: 30001236
Hum Pathol. 2021 Oct;116:1-11
pubmed: 34153307
Int J Surg Pathol. 2012 Feb;20(1):19-28
pubmed: 21791489
Am Health Drug Benefits. 2018 May;11(3):118-127
pubmed: 29910844
Histopathology. 2019 Aug;75(2):174-184
pubmed: 30895640
Pathology. 2021 Oct;53(6):720-727
pubmed: 33947521
Nephrol Dial Transplant. 2011 May;26(5):1677-82
pubmed: 20864552
Am J Nephrol. 2021;52(2):98-107
pubmed: 33752206
Abdom Imaging. 1995 Nov-Dec;20(6):569-71
pubmed: 8580756
Hum Pathol. 2014 Jan;45(1):59-64
pubmed: 24182559
Am J Surg Pathol. 2006 Feb;30(2):141-53
pubmed: 16434887
Kidney Int. 2002 Jun;61(6):2201-9
pubmed: 12028461
Int Braz J Urol. 2011 Jan-Feb;37(1):29-32;discussion 33-4
pubmed: 21385477
Cancer Sci. 2012 Mar;103(3):569-76
pubmed: 22145865
Ann Diagn Pathol. 2000 Oct;4(5):311-5
pubmed: 11073338
Am J Surg Pathol. 2016 Jan;40(1):60-71
pubmed: 26414221
Biomedicines. 2022 Mar 11;10(3):
pubmed: 35327459
Medicine (Baltimore). 1990 Jul;69(4):217-26
pubmed: 2374506
Am J Surg Pathol. 2014 Nov;38(11):1457-67
pubmed: 25093518
Urology. 1994 Oct;44(4):497-501
pubmed: 7941189
Am J Surg Pathol. 2018 Sep;42(9):1156-1165
pubmed: 29851703
Am J Surg Pathol. 2015 Jul;39(7):873-88
pubmed: 25970682
Am J Surg Pathol. 2013 Oct;37(10):1490-504
pubmed: 24025520
Biomedicines. 2022 Jan 29;10(2):
pubmed: 35203531
BMJ Clin Evid. 2010 Jul 19;2010:
pubmed: 21418665
Eur Urol. 2018 Oct;74(4):487-488
pubmed: 30029819
J Am Soc Nephrol. 2019 Jan;30(1):127-135
pubmed: 30559143
Lancet. 1999 Jul 10;354(9173):93-9
pubmed: 10408483
Hum Pathol. 2021 Aug;114:9-18
pubmed: 33961838
Arch Pathol Lab Med. 2003 Feb;127(2):E89-92
pubmed: 12562261
Am J Surg Pathol. 2015 Jul;39(7):889-901
pubmed: 25970683
Eur Urol. 2018 Oct;74(4):483-486
pubmed: 29941307